"Altogether, I see no reason that MLSS should trade for less than
its 52-week high of $3.05 if and when they announce a hospital win on the medical side of their business, especially in light of the fact that they are now partnered with Premier. That share price equates to approximately 75% returns from current levels."
Już przy tych marnych 3 USD za akcję kapitalizacja spółki matki wyniosłaby ok. 530 mln zł.
A jak słusznie pisze autor artykułu :
"Investors who bought into MLSS's recent
equity offering mentioned earlier did not pay $2.15/share for the dental business. They paid that price because of the possibility of explosive revenu and EPS growth fromInvestors who bought into MLSS's recent
equity offering mentioned earlier did not pay $2.15/share for the dental business. They paid that price because of the possibility of explosive revene and EPS growth from CompuFlo and CathCheck."
To ile my z tym CompuFlo and CathCheck powinniśmy kosztować?